Data / Form D filings / Attralus, Inc.
Attralus, Inc.: Form D filings
Attralus, Inc., a biotechnology company in Burlingame, CA, filed 3 Form D notices with the SEC between 2019 and 2024. The latest, on February 9, 2024, reports $56 million sold of a $56 million offering to 12 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 337 C Beach Road, Burlingame, CA, 94010
- Phone
- (415) 410-3268
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2019
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1797582
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 9, 2024 | New notice | $55,999,931 | $55,999,931 | 12 | Jan 26, 2024 | sec.gov | |
| Sep 24, 2021 | New notice | $116,599,889 | $116,599,889 | 22 | Aug 31, 2021 | sec.gov | |
| Dec 27, 2019 | New notice | Indefinite | $175,000 | 5 | Dec 13, 2019 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Mark Timney | Executive Officer, Director | |
| Richard Gaster | Director | |
| Mehdi Khodadad | Executive Officer | |
| Corey Goodman | Director | |
| Glen Firestone | Executive Officer | |
| Rahul Kakkar | Director | |
| Gregory Bell | Executive Officer | |
| Spencer Guthrie | Executive Officer | |
| James Testa | Executive Officer | |
| Jake Bauer | Director | |
| Nancy Miller-Rich | Director | |
| Alex Denner | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Feb 5, 2024 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Attralus, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.